Ompekimig

奥派奇米单抗

Report date: 2025/11/11 17:42:40

Base Information

Drug NameOmpekimig
Drug Alias NamePF-07264660
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody
Mechanisms of ActionInterleukin-4 inhibitorsInterleukin-13 inhibitorsInterleukin-33 inhibitors
TargetsInterleukin-4Interleukin-13Interleukin-33
Therapy Area/IndicationsDermatitis, Atopic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPoland +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncWyeth BioPharma Division of Wyeth Pharmaceuticals LlcPfizer Investment Co Ltd
Inactive CompaniesN/A
Active IndicationsDermatitis, Atopic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A